Michelle Lubetzky

Michelle Lubetzky

Auto-generated profile, based on publicly available information

Michelle Lubetzky

Division of Nephrology, Weill Cornell Medicine , New York, NY, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2021 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
MLMichelle Lubetzky
Michelle Lubetzky
ETEkamol Tantisattamo
Ekamol Tantisattamo
MMMiklos Z. Molnar
Miklos Z. Molnar
KLKrista L Lentine
Krista L Lentine
ABArpita Basu
Arpita Basu
TATarek Alhamad
Tarek Alhamad
The return to dialysis after allograft failure is associated with increased morbidity and mortality. This transition is made more complex by the rising numbers of patients who seek repeat transplantation and therefore may have indications for remaining on low levels of immunosuppression, despite the potential increased morbidity. Management strategies vary across providers, driven by limited data on how to transition off immunosuppression as the allograft fails and a paucity of randomized controlled trials to support one approach over another. In this review we summarize the current data available for management and care of the failing allograft. Additionally, we discuss a suggested plan for immunosuppression weaning based upon availability of re-transplantation and residual allograft function. We propose a shared-care model in which there is improved coordination between transplant providers and general nephrologists so that immunosuppression management and preparation for renal replacement therapy and/or repeat transplantation can be conducted with the goal of improved outcomes and decreased morbidity in this vulnerable patient group.

1 July 2020 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
MLMichelle Lubetzky
Michelle Lubetzky
MAMeredith J Aull
Meredith J Aull
RCRebecca Craig-Schapiro
Rebecca Craig-Schapiro
JLJohn R Lee
John R Lee
JMJehona Marku-Podvorica
Jehona Marku-Podvorica
DDDarshana M Dadhania
Darshana M Dadhania
Background: Kidney graft recipients receiving immunosuppressive therapy may be at heightened risk for coronavirus disease 2019 (Covid-19) and adverse outcomes. It is therefore important to characterize the clinical course and outcome of Covid-19 in this population and identify safe therapeutic strategies. Methods: We performed a retrospective chart review of 73 adult kidney graft recipients evaluated for Covid-19 from 13 March to 20 April 2020. Primary outcomes included recovery from symptoms, acute kidney injury, graft failure and case fatality rate. Results: Of the 73 patients screened, 54 tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)—39 with moderate to severe symptoms requiring hospital admission and 15 with mild symptoms managed in the ambulatory setting. Hospitalized patients were more likely to be male, of Hispanic ethnicity and to have cardiovascular disease. In the hospitalized group, tacrolimus dosage was reduced in 46% of patients and mycophenolate mofetil (MMF) therapy was stopped in 61% of patients. None of the ambulatory patients had tacrolimus reduction or discontinuation of MMF. Azithromycin or doxycycline was prescribed at a similar rate among hospitalized and ambulatory patients (38% versus 40%). Hydroxychloroquine was prescribed in 79% of hospitalized patients. Graft failure requiring hemodialysis occurred in 3 of 39 hospitalized patients (8%) and 7 patients died, resulting in a case fatality rate of 13% among Covid-19-positive patients and 18% among hospitalized Covid-19-positive patients. Conclusions: Data from our study suggest that a strategy of systematic triage to outpatient or inpatient care, early management of concurrent bacterial infections and judicious adjustment of immunosuppressive drugs rather than cessation is feasible in kidney transplant recipients with Covid-19.

27 February 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
AVAkanksha Verma
Akanksha Verma
TMThangamani Muthukumar
Thangamani Muthukumar
HYHua Yang
Hua Yang
MLMichelle Lubetzky
Michelle Lubetzky
MCMichael F. Cassidy
Michael F. Cassidy
MSManikkam Suthanthiran
Manikkam Suthanthiran
BACKGROUND: RNA sequencing (RNA-Seq) is a molecular tool to analyze global transcriptional changes, deduce pathogenic mechanisms, and discover biomarkers. We performed RNA-Seq to investigate gene expression and biological pathways in urinary cells and kidney allograft biopsies during an acute rejection episode and to determine whether urinary cell gene expression patterns are enriched for biopsy transcriptional profiles. METHODS: We performed RNA-Seq of 57 urine samples collected from 53 kidney allograft recipients (patients) with biopsies classified as acute T cell–mediated rejection (TCMR; n = 22), antibody-mediated rejection (AMR; n = 8), or normal/nonspecific changes (No Rejection; n = 27). We also performed RNA-Seq of 49 kidney allograft biopsies from 49 recipients with biopsies classified as TCMR ( n = 12), AMR ( n = 17), or No Rejection ( n = 20). We analyzed RNA-Seq data for differential gene expression, biological pathways, and gene set enrichment across diagnoses and across biospecimens. RESULTS: We identified unique and shared gene signatures associated with biological pathways during an episode of TCMR or AMR compared with No Rejection. Gene Set Enrichment Analysis demonstrated enrichment for TCMR biopsy signature and AMR biopsy signature in TCMR urine and AMR urine, irrespective of whether the biopsy and urine were from the same or different patients. Cell type enrichment analysis revealed a diverse cellular landscape with an enrichment of immune cell types in urinary cells compared with biopsies. CONCLUSIONS: RNA-Seq of urinary cells and biopsies, in addition to identifying enriched gene signatures and pathways associated with TCMR or AMR, revealed genomic changes between TCMR and AMR, as well as between allograft biopsies and urinary cells.

11 July 2019 in JCI Insight
Verified
Journal Article
Open access
PDF file
FMFranco B. Mueller
Franco B. Mueller
HYHua Yang
Hua Yang
MLMichelle Lubetzky
Michelle Lubetzky
AVAkanksha Verma
Akanksha Verma
JLJohn R. Lee
John R. Lee
TMThangamani Muthukumar
Thangamani Muthukumar
Acute rejection of human allografts has been viewed mostly through the lens of adaptive immunity, and the intragraft landscape of innate immunity genes has not been characterized in an unbiased fashion. We performed RNA sequencing of 34 kidney allograft biopsy specimens from 34 adult recipients; 16 were categorized as Banff acute T cell–mediated rejection (TCMR) and 18 as normal. Computational analysis of intragraft mRNA transcriptome identified significantly higher abundance of mRNA for pattern recognition receptors in TCMR compared with normal biopsies, as well as increased expression of mRNAs for cytokines, chemokines, interferons, and caspases. Intragraft levels of calcineurin mRNA were higher in TCMR biopsies, suggesting underimmunosuppression compared with normal biopsies. Cell-type-enrichment analysis revealed higher abundance of dendritic cells and macrophages in TCMR biopsies. Damage-associated molecular patterns, the endogenous ligands for pattern recognition receptors, as well markers of DNA damage were higher in TCMR. mRNA expression patterns supported increased calcium flux and indices of endoplasmic, cellular oxidative, and mitochondrial stress were higher in TCMR. Expression of mRNAs in major metabolic pathways was decreased in TCMR. Our global and unbiased transcriptome profiling identified heightened expression of innate immune system genes during an episode of TCMR in human kidney allografts.

8 February 2021 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
TATarek Alhamad
Tarek Alhamad
MLMichelle Lubetzky
Michelle Lubetzky
KLKrista L Lentine
Krista L Lentine
EEEmmanuel Edusei
Emmanuel Edusei
RPRonald Parsons
Ronald Parsons
DDDarshana M. Dadhania
Darshana M. Dadhania
Kidney allograft failure and return to dialysis carries a high risk of morbidity. A practice survey was developed by the AST Kidney Pancreas Community of Practice workgroup and distributed electronically to the AST members. There were 104 responders that represented 92 kidney transplant centers. Most survey respondents were transplant nephrologists at academic centers. The most common approach to immunosuppression management was to withdraw the anti‐metabolite first (73%), while 12% responded they would withdraw calcineurin inhibitor first. More than 60% reported that the availability of a living donor is the most important factor in the decision to taper immunosuppression, followed by the risk of infection, risk of sensitization, frailty, and side effects of medications. More than half of respondents reported that embolization was either not available or offered to less than 10% as an option for surgical intervention. More than half reported that ≤50% of failed allograft patients were re‐listed before dialysis, and less than a quarter of transplant nephrologists perform frequent follow‐ups with their failed allograft patients after dialysis. This survey demonstrates a heterogeneity in the care of patients with a failing allograft and the need for more evidence to guide improvements in clinical practice related to transition of care.

19 February 2021 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
LZLisa T. Zhang
Lisa T. Zhang
LWLars F. Westblade
Lars F. Westblade
FIFatima Iqbal
Fatima Iqbal
MTMichael R. Taylor
Michael R. Taylor
ACAlice Chung
Alice Chung
JLJohn Richard Lee
John Richard Lee